SCHEMBL15041607

SCHEMBL15041607

CN1CCOCC1Oc1ccc(Nc2ncc3cc(C(=O)c4ccccc4)c(=O)n(C4Cc5ccccc5C(=O)C4(C)C)c3n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 7/20 0.36
TNK2 Q07912 3/20 0.36
PDGFRB P09619 3/20 0.35
PDGFRA P16234 3/20 0.35
FGFR1 P11362 3/20 0.35
SLC2A1 P11166 1/20 0.35
PKMYT1 Q99640 1/20 0.35
CDK4 P11802 3/20 0.34
CCND1 P24385 3/20 0.34
CCNA2 P20248 3/20 0.34
CDK2 P24941 3/20 0.34
WEE1 P30291 2/20 0.34
CSF1R P07333 2/20 0.34
DAPK1 P53355 2/20 0.34
ABL1 P00519 2/20 0.34
KIT P10721 2/20 0.34
MAPK14 Q16539 2/20 0.34
EGFR P00533 2/20 0.34
FGFR2 P21802 1/20 0.34
FGFR4 P22455 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035572 0.94 TNK2 (0.35) SRCTNK2PDGFRBPDGFRAFGFR1
SCHEMBL15041296 0.82 SRC (0.36) SRCTNK2PDGFRBPDGFRAFGFR1
SCHEMBL15035368 0.76 TNK2 (0.35) SRCTNK2PDGFRBPDGFRAFGFR1
SCHEMBL15041430 0.73 SYK (0.34) SRCTNK2FGFR1CSF1RDAPK1
SCHEMBL15035464 0.73 CAMK2D (0.43) SRCTNK2PDGFRBPDGFRAFGFR1
SCHEMBL15035545 0.69 MAP4K1 (0.45) TNK2FGFR1CDK4CCND1WEE1
SCHEMBL15041809 0.69 CDK4 (0.49) TNK2PDGFRBFGFR1CDK4CCND1
SCHEMBL15041547 0.69 CDK4 (0.48) PDGFRBFGFR1CDK4CCND1CCNA2
SCHEMBL15035379 0.68 CDK4 (0.44) TNK2PDGFRBFGFR1CDK4CCND1
SCHEMBL15041542 0.68 PTK2 (0.40) SRCTNK2PDGFRBFGFR1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 SRC 26/4885TNK2 7/4885PDGFRB 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.